Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
NCT ID: NCT00915603
Last Updated: 2014-12-22
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
113 participants
INTERVENTIONAL
2009-07-31
2014-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
intolerable toxicity occurs. Outcomes will be assessed for each treatment arm
separately. This trial is not intended to compare treatment arms primarily. Any such analyses are exploratory and will be conducted without adjustment for multiple hypothesis testing.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
paclitaxel/bevacizumab/everolimus
Systemic Therapy
Everolimus
Everolimus 10mg PO daily continuously for all 28 days of a cycle
Bevacizumab
Bevacizumab 10mg/kg IV Days 1 and 15 of 28 day cycle
Paclitaxel
Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
paclitaxel/bevacizumab/placebo
Systemic Therapy
Placebo
Placebo PO daily continuously for all 28 days of a cycle
Bevacizumab
Bevacizumab 10mg/kg IV days 1 and 15 of 28 day cycle
Paclitaxel
Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Everolimus
Everolimus 10mg PO daily continuously for all 28 days of a cycle
Bevacizumab
Bevacizumab 10mg/kg IV Days 1 and 15 of 28 day cycle
Paclitaxel
Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
Placebo
Placebo PO daily continuously for all 28 days of a cycle
Bevacizumab
Bevacizumab 10mg/kg IV days 1 and 15 of 28 day cycle
Paclitaxel
Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Histologically confirmed invasive breast cancer, locally unresectable or metastatic.
3. No prior chemotherapy for MBC. Patients may have received adjuvant or
neoadjuvant chemotherapy (including taxanes and/or bevacizumab) as long as
treated was completed \>12 months prior to relapse. Prior hormonal therapy in the
adjuvant or metastatic setting will be permitted.
4. Prior hormonal therapy in the adjuvant or metastatic setting is permitted. Estrogen receptor positive patients should be considered candidates for chemotherapy.
5. HER2-negative breast cancer, defined as follows:
* FISH-negative (FISH ratio \<2.2), or
* IHC 0-1+, or
* IHC 2-3+ AND FISH-negative (FISH ratio \<2.2).
6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
7. Adequate hematologic function, defined by:
· Absolute neutrophil count (ANC) \>1500/mm3
* Platelet count \>=100,000/mm3
* Hemoglobin \>9 g/dL
8. Adequate liver function, defined by:
· AST and ALT \<=2.5 x the upper limit of normal (ULN) or \<=5 x ULN in
presence of liver metastases
* Total bilirubin \<=1.5 x ULN
9. Adequate renal function, defined by:
· Serum creatinine \<=1.5 x ULN or calculated creatinine clearance of
\>=40 ml/min
10. International normalized ratio (INR) \<=1.5 or prothrombin time (PT)/partial
thromboplastin time (PTT) within normal limits (WNL) of the institution (if patient is not on anti-coagulation therapy). Patients receiving anti-coagulation treatment with an agent such as warfarin or heparin are eligible if the INR is stable and within the therapeutic range prior to study treatment initiation.
11. Adequate lipid profile: total cholesterol \<=300 mg/dL OR \<=7.75 mmol/L and fasting triglyceride 2.5 x ULN. Note: In case one or both of these thresholds are exceeded,the patient can only be included after initiation of appropriate lipid lowering medication.
12. Patients with proteinuria at screening as demonstrated by either:
· Urine protein creatinine (UPC) ration \>1.0 at screening
or
* Urine dipstick for proteinuria \>=2+ (patients discovered to have
\>=2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour
urine collection and must demonstrate \<1 g of protein in 24 hours to be
eligible).
13. Measurable disease by RECIST criteria.
14. Life expectancy \>=12 weeks.
15. Ability to swallow oral medications.
16. Adequate cardiac function, defined by baseline left ventricular ejection fraction (LVEF) value \>= normal per institutional guidelines by MUGA scan or
echocardiogram (ECHO).
17. Adequate recovery from recent surgery.
* Major surgical procedure \>28 days from study entry
* Minor surgical procedure \>7 days from study entry (Portacath placement
excepted - patients can start treatment \<7 days after portacath placement.)
18. Patients with previous history of invasive cancers (including breast cancer) are eligible if definitive treatment was completed more than 5 years prior to initiating current study treatment, and there is no evidence of recurrent disease.
19. Patient must be accessible for treatment and follow-up.
20. All patients must be able to understand the investigational nature of the study and give written informed consent prior to study entry.
\-
Exclusion Criteria
2. Previous treatment with an m-TOR inhibitor (sirolimus, temsirolimus, everolimus) or anti-angiogenesis agent unless:
* in the adjuvant setting, and
* \>=12 months prior to recurrence.
3. Previous radiotherapy for metastatic disease completed \<2 weeks prior to study treatment initiation.
4. Patients who are current receiving systemic cancer therapy or have received
previous systemic therapy within 4 weeks of the start of study drug (e.g.
chemotherapy, antibody therapy, targeted agents).
5. Women who are pregnant or lactating. All patients with reproductive potential must agree to use effective contraception from time of study entry until at least 3 months after the last administration of study drug.
6. Uncontrolled hypertension defined as systolic blood pressure \>150 mmHg or
diastolic pressure \>100 mmHg, despite optimal medical management.
7. Concurrent use of CYP3A4 inhibitors and inducers from 72 hours prior to initiation of study treatment until the end of treatment with everolimus.
8. Cardiac disease, including: congestive heart failure (CHF) \> Class II per New York Heart Association (NYHA) classification; unstable angina (anginal symptoms at rest) or new-onset angina (i.e., began within the last 3 months), or myocardial infarction within the past 6 months; symptomatic CHF, unstable angina pectoris, or cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.
9. History of stroke or transient ischemic attack within 6 months prior to first
bevacizumab dose.
10. Patients with any non-healing wound, ulcer, or long-bone fracture.
11. Patients with clinical history of hemoptysis or hematemesis.
12. Patients with any history of a bleeding diathesis or coagulopathy.
13. Patients with a PEG or G tube cannot be enrolled into this trial.
14. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to beginning bevacizumab.
15. Patients with an impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
16. Patients who have any severe and/or uncontrolled medical conditions or other
conditions that could affect their participation such as:
* severe impaired lung functions as defined as spirometry and DLCO that is 50% of the normal predicted value and/or 02 saturation that is 88% or less at rest on room air
* uncontrolled diabetes as defined by fasting serum glucose \>1.5 x ULN.
17. History of any other disease, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug, or that might affect interpretation of the results of this study, or render the subject at high risk for treatment complications.
18. History of hypersensitivity to Cremophor EL (polyoxyethylated castor oil) or a drug formulated in Cremophor EL, such as paclitaxel.
19. Patients may not receive any other investigational or anti-cancer treatments while participating in this study.
20. Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Topical or inhaled corticosteroids are allowed.
21. Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period.
22. Concurrent severe, uncontrolled infection or intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
23. Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus) or its excipients.
24. Patients with a known HIV seropositivity.
\-
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
SCRI Development Innovations, LLC
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Denise A. Yardley, M.D.
Role: STUDY_CHAIR
SCRI Development Innovations, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wilshire Oncology Medical Group
LaVerne, California, United States
Eastern Connecticut Hematology Oncology
Norwich, Connecticut, United States
Aventura Medical Center
Aventura, Florida, United States
Florida Cancer Specialists
Fort Myers, Florida, United States
Mercy Hospital
Portland, Maine, United States
Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
National Capital Clinical Research Associates
Bethesda, Maryland, United States
Oncology Hematology Care
Cincinnati, Ohio, United States
Mid Ohio Oncology/Hematology, Inc./ The Mark H. Zangmeister Center
Columbus, Ohio, United States
South Carolina Oncology Associates, PA
Columbia, South Carolina, United States
Chattanooga Oncology Hematology Associates
Chattanooga, Tennessee, United States
Tennessee Oncology, PLLC
Nashville, Tennessee, United States
Texas Oncology
Dallas, Texas, United States
Fairfax Northern Virginia Hem-Onc
Fairfax, Virginia, United States
Virginia Cancer Institute
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCRI BRE 154
Identifier Type: -
Identifier Source: org_study_id